Table 2.
Ribavirin pharmacokinetic parameters in the single and multiple dose phases.
| Initial single dose | Final multiple dose | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Tmax(hr) | Cmax (ng mL−1) | AUC(0,12 hr)(μg.hr mL−1) | T1/2 (hr) | Tmax (hr) | Cmax*†(ng mL−1) | AUC(0,12 hr)*†(μg.hr mL−1) | T1/2 (hr) | RAUC | |
| Sustained virological responders (n =5) | 3.0 (3.0–3.0) | 660 (399–1013) | 4.1 (2.8–6.6) | 30.6 (23.8–41.4) | 3.0 (1.1–6.5) | 3484 (2645–4209) | 37.8 (29.3–43.9) | 305 (243–387) | 10.5 (6.4–12.4) |
| Virological responders (n =16) | 3.0 (2.2–3.4) | 576 (528–674) | 3.7 (3.5–4.5) | 26.8 (23.3–30.7) | 3.0 (1.8–7.6) | 2712 (2413–2795) | 28.7 (25.5–29.3) | 284 (261–315) | 7.1 (6.8–8.2) |
| Non-responders (n =6) | 3.0 (3.0–3.0) | 814 (483–1097) | 4.5 (3.1–6.3) | 28.7 (15.8–49.2) | 3.0 (3.0–3.0) | 2696 (1767–3295) | 26.1 (18.3–34.9) | 320 (260–346) | 9.2 (7.2–10.0) |
| Total (n =27) | 2.0 (2.5–3.3) | 628 (579–741) | 4.1 (3.8–4.8) | 27.3 (25.3–32.9) | 3.0 (2.5–5.9) | 2734 (2508–2982) | 28.9 (26.5–31.5) | 299 (277–317) | 8.3 (7.4–8.8) |
Values expressed as median. (95% confidence interval). Accumulation index (R) = AUC of week 24 / AUC of week 1.
*
P <0.05 for sustained virologic responders vs. virologic responders.
†
P <0.05 for sustained virologic responders vs. non-responders.